Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E.K. Pauli
Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
Real-Life Use of Bendamustine for B-Cell Non-Hodgkin Lymphoma in a Community Hospital in Japan-Retreatment With Bendamustine Is Safe and Feasible
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Combination of Gemcitabine and Cisplatin Is Highly Active in Women With Endometrial Carcinoma
Cancer
Cancer Research
Oncology
Simultaneous Diffuse Large B-Cell Lymphoma (Dlbcl) and Follicular Lymphoma (Fl) at the Diagnosis Has Similar Outcome as DLBCL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study
British Journal of Haematology
Hematology
